Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
NCT05573230Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve at 96 hours and Maximum Observed Concentration at 96 hours. Started Oct 2022; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05573230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573230.